Volume of reconstituted BOTOX and Diluent* (mL) to draw into dosing syringe to achieve a final volume of 10 mL
Tell your doctor if you are pregnant, intending to become pregnant, or breastfeeding before being administered Botox because it may not be suitable for you.
Call your healthcare provider or get emergency medical help if you have any of these problems after treatment with Botox:
Patients should discontinue anti-platelet therapy at least 3 days before the injection procedure. Patients on anti-coagulant therapy need to be managed appropriately to decrease the risk of bleeding. Appropriate caution should be exercised when performing a cystoscopy.
Avoiding injection near the levator palpebrae superioris may reduce the complication of ptosis. Avoiding medial lower lid injections, and thereby reducing diffusion into the inferior oblique, may reduce the complication of diplopia. Ecchymosis occurs easily in the soft eyelid tissues. This can be prevented by applying pressure at the injection sitio immediately after the injection.
Dosing in initial and sequential treatment sessions should be tailored to the individual patient based on the patient’s head and neck position, localization of pain, muscle hypertrophy, patient response, and adverse event history.
The duration of post-injection catheterization for those who developed urinary retention is also shown.
OnabotulinumtoxinA may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving Botox or Botox Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Treatment with BOTOX and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing [see Warnings and Precautions (5.
Detrusor Overactivity associated with a Neurologic Condition An intravesical instillation of diluted local anesthetic with or without sedation, or general anesthesia may be used prior to injection, per local site practice.
Xeomin and Botox both contain botulinum toxin type A, but each has distinctive characteristics that may benefit different patient populations. Xeomin's pure formulation without complexing proteins potentially offers advantages for long-term treatment and for patients concerned about developing resistance.
Must be administered by a licensed provider and reconstituted exactly as directed by the manufacturer.
Injection in the back of the hand may result in temporary difficulty performing activities. RADIESSE® may cause nodules, bumps or lumps in the back of the hand and can last up to 1 year.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of botox another drug and may not reflect the rates observed in clinical practice.